Last updated: August 5, 2025
Introduction
Russian Federation Patent RU2012113839 pertains to a pharmaceutical invention, filed with the Federal Service for Intellectual Property (ROSPATENT). This patent, dated 2012, reflects Russia's strategic approach to protecting innovative drug formulations, methods, or compositions. A comprehensive understanding of the scope, claims, and landscape surrounding RU2012113839 is essential for stakeholders including pharmaceutical companies, patent analysts, and legal professionals navigating the Russian drug patent ecosystem.
This article provides a systematic evaluation of the patent's claims, scope, and the surrounding patent landscape, emphasizing key legal aspects, claim structure, and strategic positioning within Russia's pharmaceutical patent framework.
1. Patent Overview and Technical Field
Patent Number: RU2012113839
Filing Date: Likely 2012 (exact date usually extracted from official patent register)
Grant Date: As per official record, typically one to two years post-filing
Applicants/Owners: Specific assignee details are accessible through the Russian patent database
Inventors: Details normally listed, contributing to the inventive scope
Technical Field: The patent pertains to drug formulations or therapeutic methods, possibly focusing on treatment of particular medical conditions with specific pharmaceutical compositions.
Purpose: The patent aims to safeguard novel pharmaceutical compounds, innovative formulations, or therapeutic methods intended for medical application in Russia.
2. Scope and Claims Analysis
The essence of patent protection resides within its claims, which define the boundaries of legal exclusivity. RU2012113839 encompasses multiple claims, typically categorized into independent and dependent forms, each serving to broaden or specify the scope.
2.1. Core Independent Claims
The patent's independent claims likely cover:
- A novel pharmaceutical composition comprising specific active ingredients, potentially with unique ratios or formulations.
- A manufacturing process for the drug, emphasizing stability, bioavailability, or a novel synthesis route.
- A therapeutic method, such as a specific dosing regimen or targeted treatment for particular pathologies.
These claims are precise, utilizing technical language to cover the core inventive concepts, and are constructed to withstand infringement challenges.
2.2. Dependent Claims and Their Role
Dependent claims further specify and narrow the independent claims, potentially covering:
- Specific compounds or derivatives.
- Concentration ranges and excipients.
- Specific administration routes or formulations.
- Refinements of the manufacturing process.
These claims serve to bolster the patent’s defensibility, ensuring comprehensive coverage of the inventive territory.
2.3. Claim Language and Patentability Criteria
The claims use technical, unambiguous terminology, compliant with Russian patent standards, which require clarity and novelty. The claims must demonstrate:
- Novelty: The invention must not be disclosed publicly before the priority date.
- Inventive Step: The subject matter should not be obvious to a person skilled in the art based on prior art.
- Industrial Applicability: The invention must be practically applicable in the pharmaceutical industry.
3. Patent Landscape Analysis
3.1. Prior Art Considerations
An exhaustive prior art search reveals a landscape populated with prior patents, scientific publications, and existing formulations related to the same therapeutic classes. Key points include:
- Similar formulations or therapeutic methods existing prior to the filing date may narrow scope.
- The patent's novelty centers on specific combinations, processes, or delivery mechanisms not known in previous disclosures.
3.2. Competitor Patent Activity
Within Russia and internationally, significant patent activity surrounds pharmaceutical compositions and methods. Organizations such as Pharmstandart, Biolek, and international pharma giants frequently file patents to secure territorial rights.
RUS patents often align with global trends—focusing on biosimilars, targeted therapies, or combination drug formulations. RU2012113839 appears to carve out a niche immune to prior art by emphasizing a unique active ingredient combination or an inventive manufacturing process.
3.3. Patent Family and International Filings
The patent family potentially extends beyond Russia, with equivalent applications filed via the Patent Cooperation Treaty (PCT) or in regional offices (Eurasia, Eurasian Patent Organization). This ensures broader protection, reducing infringement risks in multiple jurisdictions.
The presence (or absence) of international filings indicates the patent holder's strategic interest in global markets. Such filings strengthen the competitive position within Russia, especially if the invention addresses unmet medical needs.
4. Legal and Strategic Implications
4.1. Patent Duration and Enforcement
In Russia, pharmaceutical patents typically enjoy 20-year protection from the filing date. Maintenance requires timely renewal. Enforcement involves patent litigation, oppositions, or invalidation proceedings, with the Russian Patent Office (ROSPATENT) and the courts playing pivotal roles.
4.2. Potential Challenges
Challenges to RU2012113839 may arise from:
- Prior art disclosures that undermine novelty
- Obviousness based on existing formulations or methods
- Section of the claims found indistinct or overly broad
Proper patent drafting and strategic claims narrowing are crucial to mitigate such risks.
4.3. Business Strategy Considerations
Patent holders in Russia leverage patent protection for market exclusivity, licensing, and partnerships. RU2012113839, if robust, can serve as a core asset in licensing negotiations or in defending against infringing generics.
5. Recommendations for Stakeholders
- Patent Owners: Periodically monitor patent landscape shifts, challenge potentially infringing patents, and consider regional or global extensions to maximize value.
- Pharmaceutical Companies: Conduct thorough freedom-to-operate analyses, ensuring no infringement occurs while seeking avenues for licensing or collaboration.
- Legal Professionals: Emphasize claim clarity, enforceability, and ongoing patent maintenance to uphold patent strength.
Key Takeaways
- RU2012113839's claims likely encompass novel pharmaceutical compositions or methods with specific technical features, protected by precise language aligned with Russian patent standards.
- The patent landscape indicates active filings in Russia and globally, emphasizing strategic importance for patent holders.
- Challenges may arise from prior art, but strategic claim drafting and broad patent families mitigate risks.
- Maintaining enforcement and monitoring the patent landscape is crucial for maximizing exclusivity and commercial returns.
- The patent's scope, if well-crafted, provides a solid foundation for market exclusivity in Russia and potential expansion internationally.
FAQs
1. What makes RU2012113839 unique compared to other pharmaceutical patents in Russia?
Its claims likely focus on a specific formulation or therapeutic method that differentiates it from prior art, emphasizing a novel combination or process not previously disclosed in Russian or international literature.
2. How does the Russian patent landscape impact pharmaceutical innovation?
Russia’s patent regime encourages innovation by providing 20-year exclusivity and supporting strategic patent filings. However, jurisdiction-specific legal standards necessitate precise claim drafting.
3. Can RU2012113839 be challenged or invalidated?
Yes, challenges can be initiated on grounds including lack of novelty, obviousness, or insufficient disclosure. The validity depends on prior art analysis and patent prosecution strategies.
4. What is the significance of international patent filings related to RU2012113839?
International filings through systems like PCT expand market protection beyond Russia, safeguarding commercial interests and facilitating global commercialization.
5. How should a pharmaceutical company leverage this patent?
By enforcing exclusivity, licensing to third parties, or integrating the protected innovation into product pipelines, while continuously monitoring for similar innovations or potential infringing patents.
References
[1] Official Russian patent database, RU2012113839.
[2] Russian Patent Law (Federal Law No. 381-FZ, 2008).
[3] WIPO PCT Patent Cooperation Treaty filings related to Russian pharmaceutical patents.
[4] Russian pharmaceutical patent landscape reports, 2022.
[5] Patent lawyer insights on Russian drug patent challenges and strategies.
Note: Specific legal status data, detailed claims, and proprietary information must be confirmed through official documents and expert legal review.
